Biointron’s Q2 2025 Antibody Industry Report aims to explore the events and trends of the biopharmaceutical industry in April, May, and June. This quarter, 5 novel monoclonal antibody drugs have been approved by at least one regulatory agency around the world: three from US, one from EU, and one from China.
Linvoseltamab (Lynozyfic)
Nipocalimab (Imaavy)
Telisotuzumab Vedotin (Emrelis)
Trastuzumab Rezetecan
Clesrovimab (Enflonsia)
Instead of M&As, Q2 2025 saw pharmaceutical companies making large licensing transactions, such as one collaboration with a potential $11.1 billion value. Investment into antibody drug startups have focuses across novel antibody modalities and autoimmune disease targets.
Gain exclusive insights into current trends such as:
5 novel antibody drugs approved for the first time in Q2
Top 10 antibody drug deals, including licensing agreements, strategic partnerships, and funding rounds of up to US$11.1B
Current research into the disease area of non-small cell lung cancer (NSCLC)
Multi-payload antibody-drug conjugates as a recent innovation
A list of antibody drugs with soon approaching approval action dates to keep an eye out for in Q3 2025
